Status: In-stock

It is one of impurity present in Sitagliptin. Sitagliptin is a dipeptidyl peptidase inhibitor, which increases levels of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide that decreased levels of glucagon. Reduced inhibition of incretins increases insulin synthesis and decreases glucagon release in a manner dependent on glucose concentrations. These effects lead to an overall increase in blood glucose control which is demonstrated by reduced glycosylated hemoglobin, which is used for the management of type 2 diabetes mellitus.

Additional information on (E)-1-(3-(trifluoromethyl)-5 | 6-dihydro-[1 | 2 | 4]triazolo[4 | 3-a]pyrazin-7(8H)-yl)-4-(2 | 4 | 5-trifluorophenyl)but-2-en-1-one

Catalogue No. VE009354
Molecular Formula C16H12F6N4O
Molecular Weight 390.28 g/mol
Parent drug Sitagliptin
IUPAC Name (E)-1-(3-(trifluoromethyl)-5, 6-dihydro-[1, 2, 4]triazolo[4, 3-a]pyrazin-7(8H)-yl)-4-(2, 4, 5-trifluorophenyl)but-2-en-1-one
Synonyms N/A
References Gallwitz, B. (2007). Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. Vascular Health and Risk Management, 3(2), 203–210. https://doi.org/10.2147/vhrm.2007.3.2.203
Status In-stock

Request a quote

We Respond Within a Few Hours - Whether You're a New or Existing Client

Payment Made Simple: All major Credit/Debit cards accepted

Streamlined 3-Step Process from Quotes to Orders:

Product name:


"*" indicates required fields

Products quotation
This field is for validation purposes and should be left unchanged.